Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (December 2022)
28 slides from Island Pharmaceuticals's investor presentation, Dec 5, 2022
Slide 1: ISLA-101 trial update and investor presentation
5 December 2022 For personal use only ASX Announcement ISLA-101 trial update and investor presentation MELBOURNE Australia, 5 December 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to provide a brief
Slide 2: About Island Pharmaceuticals
About Island Pharmaceuticals Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with For personal use only a well-established safety profile, being repurposed for the pr
Slide 3: Solving Urgent Viral Disease Threats
For personal use only SOLVING URGENT VIRAL DISEASE THREATS (ASX: ILA) Spark Plus December 2022 ISLAND PHARMACEUTICALS LIMITED 1 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021
Slide 4: Disclaimer
DISCLAIMER This presentation has been prepared by Island Pharmaceuticals given in this presentation is given for illustrative purposes only and could cause actual results or trends to differ materially, including but For personal use only Limited (ABN 641 183 842) (Company or Island Pharmaceuticals)
Slide 5: Island Pharmaceuticals mid clinical-stage drug repurposing company
For personal use only Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases ISLAND PHARMACEUTICALS LIMITED 3 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021
Slide 6: Island at a Glance
ISLAND AT A GLANCE For personal use only Advancing lead drug Dengue infects +390 million year Major market potential ISLA-101 toward Phase 2 No current pharmaceutical treatment In mosquito-borne “PEACH”* clinical trial for the for the disease. Limited access to only diseases, exacerbated by preventi
Slide 7: The Benefits of Drug Repurposing
THE BENEFITS OF DRUG REPURPOSING For personal use only Reduced time, cost and risk ISLAND PHARMACEUTICALS LIMITED 5 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021
Slide 8: The Challenge
For personal use only THE CHALLENGE ISLAND PHARMACEUTICALS LIMITED 6 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021
Slide 9: Dengue fever is the most rapidly spreading mosquito-borne virus infection
For personal use only “DENGUE FEVER IS THE MOST RAPIDLY SPREADING MOSQUITO-BORNE VIRUS INFECTION IN THE WORLD.” World Health Organisation, 13 October 2022 ISLAND PHARMACEUTICALS LIMITED 7 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021
Slide 10: Mosquito Borne Viruses: Global Challenges
MOSQUITO BORNE VIRUSES: GLOBAL CHALLENGES For personal use only Nov 23, 2021 Dec 1, 2021 The researchers found 2.4 times the rate of arbovirosis as originally reported, including coinfections, suggesting underestimation of the incidence of the three viruses. However, future research is needed to pro
Slide 11: Why Dengue as a First Target for ISLA-101?
WHY DENGUE AS A FIRST TARGET FOR ISLA-101? SIGNIFICANT UNMET NEED FOR DISEASE WITH INCREASING INCIDENCE For personal use only Significant unmet need (3.9 billion people at risk) Increasing spread to US, EU and Australia ISLA-101 has both therapeutic and prophylactic potential Strong animal and human
Slide 12: Dengue Is a Widespread Issue
DENGUE IS A WIDESPREAD ISSUE For personal use only Dengue outbreaks occurred in many countries of the world in the Americas, Africa, the Middle East, Asia, and the Pacific Islands. ISLAND PHARMACEUTICALS LIMITED https://www.healthmap.org/dengue/en/ visited November 1, 2022 10 Investor INVESTOR Prese
Slide 13: Dengue in 2050 – A Global Disease
DENGUE IN 2050 – A GLOBAL DISEASE For personal use only Prediction based on projections of future temperatures, rainfall, and mosquito populations (NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford.) ISLAND PHARMACEUTICALS LIMITED https://earthobserv
Slide 14: ISLA-101
For personal use only ISLA-101 ISLAND PHARMACEUTICALS LIMITED 12 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021
Slide 15: ISLA-101 Repurposed Drug Dramatically Reduces Development Time, Risk and Cost
ISLA-101 REPURPOSED DRUG DRAMATICALLY REDUCES DEVELOPMENT TIME, RISK AND COST For personal use only ISLA-101, Demonstrated Strong regulatory Speed to market Capitalising on originally a as safe in history and & early revenue millions spent cancer drug humans acceptance potential Originally identifie
Slide 16: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES (A SUBGROUP OF ARBOVIRUSES) IN MULTIPLE MODELS OF INFECTION For personal use only • In in-vitro models using fresh human cells, Dengue 1-4 ISLA-101 has demonstrated broad anti-viral activity • In animal models, ISLA-101 is pr
Slide 17: Prevents Animal Deaths from Lethal Dengue
PREVENTS ANIMAL DEATHS FROM LETHAL DENGUE For personal use only ISLA-101 has also been shown to be protective in animal models of both dengue and Zika Virus. Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 ISL
Slide 18: Pathway / Timing to Clinical Trials
PATHWAY / TIMING TO CLINICAL TRIALS MULTIPLE WORKSTREAMS WILL TAKE US TO FDA REVIEW OF OUR IND For personal use only 1. Manufacturing complete, awaiting 30 day stability. 2. Finalization of CMC section of IND IND submitted Mandatory Island trial 30-day review commences!* period at FDA 3. Completion
Slide 19: Manufacturing Progress
MANUFACTURING PROGRESS For personal use only Manufactured capsules Packaged bottles being processed awaiting stability results ISLAND PHARMACEUTICALS LIMITED 17 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021
Slide 20: Phase II Dengue (PEACH) Trial Study in Detail
PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL “PEACH" STUDY- A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY FOR THE PROPHYLACTIC EXAMINATION OF AN ANTIVIRAL IN A DENGUE CHALLENGE For personal use only MODEL Administer ISLA-101 daily Phase II trial protocol Up to 4 cohorts/4 arms Incl
Slide 21: Phase 1 Control Data Demonstrates Benefit of Challenge Study Approach
PHASE 1 CONTROL DATA DEMONSTRATES BENEFIT OF CHALLENGE STUDY APPROACH For personal use only A Phase 1 challenge study conducted by Walter Reed and SUNY Upstate forms the basis of Island’s PEACH study control data, and enabled unprecedented ability to monitor dengue symptoms, including: • Abdominal p
Slide 22: The Commercial Opportunity
For personal use only THE COMMERCIAL OPPORTUNITY ISLAND PHARMACEUTICALS LIMITED 20 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021
Slide 23: Commercial Opportunity
COMMERCIAL OPPORTUNITY For personal use only Prophylactic for National Government Priority Review travelers Military outbreaks Stockpiles Voucher Tropical area travellers opportunity: Military opportunity: Endemic area opportunity: • Comparable to malaria market – • Isla is partnering with army (CRA
Slide 24: Advancing Our Pipeline
ADVANCING OUR PIPELINE For personal use only Viruses to target prioritised by: Exemplary viruses that met these criteria include: • Zika virus Medical relevance for the Americas, Europe, Australia/NZ • Human respiratory syncytial virus • Human rhinovirus • Echovirus • Human adenovirus Significant un
Slide 25: Upcoming Milestones
UPCOMING MILESTONES For personal use only H1 FY 2022 H2 FY 2022 H1 FY 2023 H2 FY 2023 (July-Dec 2021) (Jan-June 2022) (July-Dec 2022) (Jan-June 2023) New drug product Clinical material • Open IND Sign SUNY CTA manufacturer manufactured • Screening, Announce Principal secured Investigator • C
Slide 26: Board, Management & Scientific Board
BOARD, MANAGEMENT & SCIENTIFIC BOARD For personal use only BOARD & MANAGEMENT TEAM Dr. Paul MacLeman Dr. David Foster Dr. Anna Lavelle Mr. Al Hansen Dr. David Brookes Executive Chair CEO & Executive Director Non-Executive Director Non-Executive Director Non-Executive Director SCIENTIFIC ADVISORY BOA
Slide 27: Corporate Snapshot
CORPORATE SNAPSHOT For personal use only ISSUED CAPITAL* Price ILA.ASX Total number of shares on issue 81,268,468 MARKET CAPITALISATION Share price (as at 2 December 2022) $0.19 Market capitalisation $15.44M Cash (30 September 2022) $3.9M SIGNIFICANT SHAREHOLDERS Dr William J Garner 21,913,098 27.06
Slide 28: Contact
For personal use only David Foster Chief Executive Officer & Executive Director dfoster@islandpharmaceuticals.com Authorized for release by Paul MacLeman, Executive Chairman Island Pharmaceuticals Limited ACN 641 183 842 www.islandpharmaceuticals.com Registered office: Suite 201, ISLAND PHARMACEUTIC
Island Pharmaceuticals — Investor Presentation (December 2022) on 6ix